ClinicalTrials.gg
CompletedNCT06716905Updated Feb 17, 2026

Safety, Tolerability, and Pharmacokinetics of ACT500 in Healthy Adult Participants

A Phase 1 interventional study of ACT500 tablets and Placebo in Non-alcoholic Steatohepatitis, sponsored by Xiamen Amoytop Biotech Co., Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-02-17.

Sponsored by Xiamen Amoytop Biotech Co., Ltd. · Phase 1, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
72
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 142 studies in Non-alcoholic Fatty Liver Disease with a site in China — 42 open to participants now, 54 under way, 5 of them phase 3. Non-alcoholic Fatty Liver Disease · China.

Enrollment
68th of 89
72 · median 112
Started
2025
with 9 others
Phase 1
18 of 142
4 open now
Registered
116th of 142
by date

Among the 142 studies in Non-alcoholic Fatty Liver Disease with a site in China, this one is the 68th largest by enrollment of the 89 interventional ones that give a count, is one of 10 that started in 2025, is one of 18 in phase 1, and was the 116th registered.

Non-alcoholic Fatty Liver Disease

1,617 studies on the registry are indexed under Non-alcoholic Fatty Liver Disease; 322 are open to participants now.

Browse Non-alcoholic Fatty Liver Disease studies →

Open to participants now

42 of the 142 studies in Non-alcoholic Fatty Liver Disease with a site in China are open now. Recruiting first, the newest first:

37 more — sign in →

All 42 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 219 Non-alcoholic Fatty Liver Disease studies recruiting now, 66 (30%) set no upper age limit and 124 (57%) stop at 75 or younger; 27 take children under 18; 55 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 142 studies in Non-alcoholic Fatty Liver Disease with a site in China, or all of them as a file.
02

Study summary

This is a single-center, randomized, double-blind, placebo-controlled Phase I clinical study, divided into two parts. The first part is a single-dose escalation study (Part1,SAD study phase), and the second part is a multiple-dose escalation study (Part2,MAD study phase). It's aimed to evaluate the safety, tolerability, and pharmacokinetics (PK) of ACT500 in healthy adult participants, and to explore possible metabolites and biomarkers of ACT500.

03

Conditions studied

  • Non-alcoholic Steatohepatitis

Keywords

  • Non-alcoholic Steatohepatitis
  • ACT500
  • NM6606
  • pharmacokinetic
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants are willing and able to sign a written form voluntarily before starting any study-related procedures and are willing to comply with all required study procedures;
  • Males or females between 18 and 55 years of age (inclusive) at the time of screening;
  • (BMI) between 19-26 kg/m\^2 (inclusive) at the time of screening, with a weight of at least 50 kg;
  • Blood pressure within the normal range at the time of screening: systolic pressure: 90-139 mmHg, diastolic pressure: 60-89 mmHg (inclusive of the critical values);
  • Participants of men and women of willing to use highly effective measures (condoms, contraceptive sponges, contraceptive gels, contraceptive films, intrauterine devices, oral or injectable contraceptives, subdermal implants, etc.) from the time of signatures of the informed consent form until 90 days after the last administration of the study medication; and women of childbearing potential must have a negative serum pregnancy tests at the time of screening and at the time of the D-1 examination;

Exclusion criteria

Exclusion Criteria:

  • Allergic to the study drug or any of its components;
  • Have previously used the study drug;
  • Have diseases, including but not limited to abnormality in liver or kidney, blood, digestive (including bleeding, infection, obstruction, or diarrhea greater than grade 1), respiratory, cardiovascular and cerebrovascular, endocrine, metabolic disorders, nervous system diseases, etc., which assessed by the investigator unsuitable for inclusion;
  • Clinical significant abnormality in vital signs, physical examination, laboratory tests, or at screening, as assessed by the investigator unsuitable for inclusion;
  • > 450ms (males), QTcF > 480ms (females) at screening [Fridericia's formula: QTcF = QT/(RR)\^1/3];
  • Estimated (eGFR) \< 90 mL/min/1.73m\^2 at screening;
  • A history of unstable cardiovascular and cerebrovascular diseases within 6 months prior to screening, including acute myocardial infarction, stroke, arrhythmia, etc.;
  • Existing liver disease or unexplained elevation of liver function tests ( (ALT), aspartate aminotransferase (AST), gamma-glutamyl transferase (GGT), alkaline phosphatase (ALP), total or direct bilirubin > 1.5× at screening or D-1, or D-1 test value is more than 50% higher than the screening test value);
  • Respiratory infections (upper and/or lower respiratory tract) treated with antibiotics within 12 weeks before screening;
  • Infectious diseases within the screening period (within 28 days before the first dose) that, in the investigator's judgment, would affect the participant's ability to participate in the trial;
  • History of tuberculosis;
  • History of malignant tumors (except for basal cell carcinoma or squamous cell carcinoma of the skin);
  • Serious trauma or surgery within 28 days before the first dose, or planning major surgery during the study period;
  • Blood donation or significant blood loss (≥400mL) within 56 days before the first dose, or having received a blood transfusion;
  • Use of any medication (including prescription drugs, over-the-counter drugs, traditional Chinese medicine, etc.) or health products within 14 days before the first dose (or 5 half-lives, whichever is longer);
  • Use of strong inhibitors or inducers of CYP450 enzymes and/or P-gp within 28 days before the first dose, or needing to continue using the above drugs during the study period;
  • Received live or attenuated vaccines within 30 days before the first dose, or planning to receive them during the study period;
  • Participated in or currently participating in other new drug or medical device clinical trials within 30 days before the first dose (or 5 half-lives, whichever is longer), or currently undergoing follow-up of another clinical study;
  • Unable to swallow oral medication, having clinically significant gastrointestinal abnormalities (such as post-gastrointestinal resection, post-gastrointestinal anastomosis, chronic diarrhea, and intestinal obstruction, etc.) or existing conditions that, in the investigator's judgment, significantly affect gastrointestinal absorption;
  • Poor venous access, unable to tolerate venipuncture, or having a history of clinically significant syncope or needle phobia as judged by the investigator;
  • History of drug or substance abuse;
  • Positive results for any of the following tests during the screening period: antibody (HIV-Ab), syphilis antibody, surface antigen (HBsAg), virus antibody (HCV-Ab);
  • Heavy smoking (defined as more than 5 cigarettes per day) or use of nicotine-containing products (such as snuff, nicotine patches, nicotine gum, e-cigarettes, simulated cigarettes, or inhalers) within 6 months before screening; or unable to quit smoking (stop nicotine intake) during the trial period;
  • A history of alcohol abuse within 90 days before screening, or positive alcohol test results at D-1; or unable to abstain from alcohol intake during the trial period; alcohol abuse is defined as an average weekly intake of more than 14 standard drinks (1 standard drink contains 14g of alcohol, such as 45ml of spirits with an alcohol concentration of 40% or 180ml of wine with an alcohol concentration of 10%);
  • Pregnant or breastfeeding women;
  • The investigator believes that the participant has other conditions that may affect compliance or are unsuitable for participation in this trial.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
72 participants (actual)

Study arms

  • Experimental
    Part 1:ACT500 Tablets

    Drug: ACT500 tablets

  • Placebo comparator
    Part 1: Placebo

    Drug: Placebo

  • Experimental
    Part 2:ACT500 Tablets

    Drug: ACT500 tablets

  • Placebo comparator
    Part 2: Placebo

    Drug: Placebo

Interventions

  • Participants will receive a single ascending oral dose of ACT500 Tablets under fasting state on the first day in Part 1

  • DrugPlacebo

    Participants will receive placebo matched to ACT500 Tablets.

  • Participants will receive multiple ascending oral dose of ACT500 Tablets under fasting state once daily for 7 days in Part 2.

  • DrugPlacebo

    Participants will receive placebo matched to ACT500 Tablets.

06

What researchers measure

Primary outcomes

  1. Adverse Event(AE)

    Time frame: SAD:Day1-8; MAD:Day1-22.

  2. Serious Adverse Event

    Time frame: SAD:Day1-8; MAD:Day1-22.

  3. body temperature

    Time frame: SAD:Day1-5; MAD:Day1,Day7-22.

  4. respiration

    Time frame: SAD:Day1-5; MAD:Day1,Day7-22.

  5. pulse

    Time frame: SAD:Day1-5; MAD:Day1,Day7-22.

  6. heart rate

    Time frame: SAD:Day1-5; MAD:Day1,Day7-22.

  7. blood pressure

    Time frame: SAD:Day1-5; MAD:Day1,Day7-22.

  8. Physical Examination

    Physical examination includes general condition, head and neck, lymph nodes, skin, chest, abdomen, and musculoskeletal system (including limbs and spine).

    Time frame: SAD:Day1,Day3-8; MAD:Day1,Day3-22.

  9. Number of Participants with 12-Lead Electrocardiogram Findings

    Time frame: SAD:Day-1,Day5 ; MAD:Day-1,Day3,Day8and D14.

  10. Number of Participants with Dynamic electrocardiogram(ECG)Findings

    Time frame: SAD:Day1; MAD:Day1,Day7.

  11. Number of Participants with Abnormal Laboratory Parameters Findings

    Time frame: SAD:Day1-8; MAD:Day1-22.

Secondary outcomes

  1. Maximum concentration (Cmax)

    Time frame: SAD:Day1-5;

  2. Time to maximum concentration(Tmax)

    Time frame: SAD:Day1-5;MAD:Day1-8

  3. The area under the plasma concentration-time curve from the time of initial dosing to the time of the last measurable concentration point (AUC0-t)

    Time frame: SAD:Day1-5;

  4. The area under the plasma concentration-time curve from the time of initial dosing to infinity (AUC0-∞)

    Time frame: SAD:Day1-5;

  5. Apparent terminal elimination half-life (t1/2).

    Time frame: SAD:Day1-5;

  6. Clearance (CL/F)

    Time frame: SAD:Day1-5;

  7. Apparent Volume of Distribution (Vd/F)

    Time frame: SAD:Day1-5;

  8. Elimination Rate Constant(Kel)

    Time frame: SAD:Day1-5;

  9. Mean Residence Time(MRT)

    Time frame: SAD:Day1-5;

  10. Steady-state trough concentration(Cmin,ss)

    Time frame: MAD:Day1-8;

  11. Steady-state peak concentration(Cmax,ss)

    Time frame: MAD:Day1-8;

  12. Average steady-state plasma concentration(Cav,ss)

    Time frame: MAD:Day1-8;

  13. Elimination half-life(t1/2,ss)

    Time frame: MAD:Day1-8;

  14. Clearance (CLss/F)

    Time frame: MAD:Day1-8;

  15. Apparent Volume of Distribution (Vd/Fss)

    Time frame: MAD:Day1-8;

  16. Accumulation Index (RAC)

    Time frame: MAD:Day1-8;

  17. The area under the plasma concentration-time curve from the time of the last dose to the time of the last measurable concentration point (AUC0-t,ss)

    Time frame: MAD:Day1-8;

  18. The area under the plasma concentration-time curve within one dosing interval after the last dose (AUC0-τ)

    Time frame: MAD:Day1-8;

  19. The area under the plasma concentration-time curve extrapolated from the last dose to infinity (AUC0-∞,ss)

    Time frame: MAD:Day1-8;

  20. Coefficient of Fluctuation (DF)

    Time frame: MAD:Day1-8;

  21. Pharmacokinetic (PK):Plasma Concentrations of ACT500

    Time frame: SAD:Day1-4;MAD:Day1-8;

  22. Changes of biomarkers after single and multiple oral dosing compared to baseline

    Time frame: SAD:Day1-5;MAD:Day1-8.

07

Study locations

1 site
  • Zhongnan Hospital of Wuhan University
    Wuhan, Hubei, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2025 to primary completion in Sep 2025, 6 months.

Of 104 industry-sponsored phase 1 interventional studies under Non-alcoholic Fatty Liver Disease, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 16. This study's 6 months is below that.

Counting every sponsor, half of 125 studies reached it within 10 months; a quarter within 5 and three quarters within 21.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 13, 2024
First posted
Dec 4, 2024
StartActual
Mar 6, 2025
Primary completionActual
Sep 22, 2025
CompletionActual
Sep 22, 2025
Last update
Feb 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06716905
Collaborators
Zhongnan Hospital
Responsible party
Sponsor
First posted
Dec 4, 2024
Start date
Mar 6, 2025
Primary completion
Sep 22, 2025
Completion
Sep 22, 2025
Last update
Feb 17, 2026

Study contacts

JianYing Huang
principal investigator · Zhongnan Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: ACT500

Start the discussion